Truist Financial's Q4 beat EPS and revenue estimates, but noninterest expenses rose and specific lending segments faced ...

Prologis (NYSE:PLD – Get Free Report) had its price target dropped by analysts at Truist Financial from $132.00 to $121.00 in ...

Truist downgraded Merck (MRK) to Hold from Buy with a price target of $110, down from $130, as part of a broader research note previewing FY25 for large-cap biopharma. The sector has ...

Truist lowered the firm’s price target on Nevro (NVRO) to $4.70 from $7 and keeps a Hold rating on the shares as part of a broader research note previewing 2025 in Medical Technology. The firm s ...

Truist Financial analyst Youssef Squali assigned a Buy rating to the stock today. The company’s shares closed yesterday at $218.46.Stay Ahead ...

Truist Financial cut shares of Sabra Health Care REIT (NASDAQ:SBRA – Free Report) from a buy rating to a hold rating in a research report report published on Friday morning, Ratings reports. They ...

CRISPR Therapeutics stock could more than double from recent prices, according to analysts from Bank of America and Truist. CRISPR Therapeutics earned approval for its first drug over a year ago ...

On Thursday, Truist Securities expressed continued confidence ... operational capabilities and its ability to capitalize on new ventures. The company's focus on organic growth and its openness ...